BEONE MEDICINES USA, INC. (FORMERLY BEIGENE USA, INC.)

Lobbying for BEONE MEDICINES USA, INC (FORMERLY BEIGENE USA, INC.)

Filing 2nd Quarter - Report

2nd Quarter (Apr 1 - June 30) 2026 · Massachusetts · House · Senate · $350,000.00 expenses · posted Jul 20, 2026

Lobbying activity 1

Health Issues

Issues related to drug pricing, including federal proposals impacting reimbursement, access, and affordability; Issues related to Medicare Drug negotiation and implementation of the Inflation Reduction Act; Pharmacy benefit manager reform legislation; Issues related to Executive Order 14297- Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients; Issues related to Most Favored Nation (MFN) pricing models

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.